Telomir Pharmaceuticals, Inc. TELO
Nov 4, 2026, 10:25 AM EST
- YTD
- -35.26%
- 1 year
- -38.94%
- Market cap
- 63.43M
- EPS (ttm)
- -1.11
- Shares out
- 29.75M
- YTD return
- -35.26%
- 1-year return
- -38.94%
- Volume
- 13.77K
- Avg volume
- 84.50K
- Open
- 0.91
- Previous close
- 0.91
- Day's range
- 0.8601 – 0.93
- 52-week range
- 0.791 – 1.58
- Price target
- 12.15 (+1311.1%)
- Earnings date
- Aug 13, 2024
2Y -3.3101 (-78.07%)
Key statistics
- Enterprise value
- 152.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 310.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 213.65K
- Total cash
- 834.64K
- Total debt
- 93.43K
- Return on equity
- -1752.69%
- Short % of float
- 3.89%
- 50-day average
- 4.61
- 200-day average
- 5.36
Analyst view
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.05.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.20 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.05 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.23 | — | — |
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- telomirpharma.com
News
TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing 
Telomir Pharmaceuticals Announces ~$5.6M Investment In PIPE Financing Through Common Stock Issuance 
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4 
Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma Models - 12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Friday's After-Market Session 
Telomir Pharmaceuticals Publishes Peer-Reviewed Preclinical Data In Biomedicine & Pharmacotherapy Titled "Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes"
Your note
Sign in to keep a note on TELO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAY SHORE TRUST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 12, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.89% | 1,151,527 | 5.37M | Sep 29, 2024 |
| Blackrock Inc. | 1.24% | 366,878 | 1.71M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 238,737 | 1.11M | Sep 29, 2024 |
| Suncoast Equity Management | 0.17% | 51,194 | 238.56K | Sep 29, 2024 |
| Bank Of New York Mellon Corporation | 0.17% | 51,364 | 239.36K | Sep 29, 2024 |
| Northern Trust Corporation | 0.16% | 48,680 | 226.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.82% | 834,700 | 3.89M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 261,970 | 1.22M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.32% | 93,887 | 437.51K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.17% | 49,772 | 231.94K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 30,433 | 141.82K | Oct 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.10% | 28,721 | 133.84K | Oct 30, 2024 |